Ratings AVITA Medical, Inc.

Equities

RCEL

US05380C1027

Real-time Estimate Cboe BZX Other stock markets 12:47:04 2024-05-21 pm EDT			5-day change	1st Jan Change
8.16 ^USD	-0.12%		-6.54%	-40.60%

May. 14	Cantor Fitzgerald Trims Price Target on Avita Medical to $21 From $22, Maintains Overweight Rating	MT
May. 14	Piper Sandler Downgrades Avita Medical to Neutral From Overweight, Price Target is $9	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Over the last twelve months, the sales forecast has been frequently revised upwards.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
AVITA MEDICAL, INC.	-40.60%	211M	C
MODERNA, INC.	+41.28%	54.04B	B-
LONZA GROUP AG	+43.57%	41.96B	A
IQVIA HOLDINGS INC.	-1.26%	41.92B	B
CELLTRION, INC.	-7.59%	28.35B	C
ICON PUBLIC LIMITED COMPANY	+12.40%	26.35B	B-
ALNYLAM PHARMACEUTICALS, INC.	-22.26%	19B	B
BIO-TECHNE CORPORATION	+7.75%	13B	B+
MEDPACE HOLDINGS, INC.	+28.86%	12.28B	C+
UNITED THERAPEUTICS CORPORATION	+24.93%	12.19B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders